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A B S T R A C T
Background and purpose: Local implementation of plan-specific quality assurance (QA) methods for intensity-
modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) treatment plans may vary be-
cause of dissimilarities in procedures, equipment and software. The purpose of this work is detecting possible
differences between local QA findings and those of an audit, using the same set of treatment plans.
Methods: A pre-defined set of clinical plans was devised and imported in the participating institute’s treatment
planning system for dose computation. The dose distribution was measured using an ionisation chamber,
radiochromic film and an ionisation chamber array. The centres performed their own QA, which was compared
to the audit findings. The agreement/disagreement between the audit and the institute QA results were assessed
along with the differences between the dose distributions measured by the audit team and computed by the
institute.
Results: For the majority of the cases the results of the audit were in agreement with the institute QA findings:
ionisation chamber: 92%, array: 88%, film: 76% of the total measurements. In only a few of these cases the
evaluated measurements failed for both: ionisation chamber: 2%, array: 4%, film: 0% of the total measurements.
Conclusion: Using predefined treatment plans, we found that in approximately 80% of the evaluated measure-
ments the results of local QA of IMRT and VMAT plans were in line with the findings of the audit. However, the
percentage of agreement/disagreement depended on the characteristics of the measurement equipment used and
on the analysis metric.
1. Introduction
Intensity-modulated radiotherapy (IMRT) and volumetric modu-
lated arc therapy (VMAT) techniques have become standard practice in
radiotherapy. Given the complexity of these delivery methods, the dose
delivery needs to be verified against calculation by the treatment
planning system (TPS) [1].
Several reports have been written regarding recommendations on
quality assurance (QA) for IMRT and VMAT plans [1–5]. Still, local
implementations of plan-specific QA methods may vary because of
differences in hardware, software and evaluation metric. To ensure
independent verification of plan-specific QA, many dosimetry audits
have been conducted using locally devised treatment plans [4,6–15].
Since the local QA equipment is also used to devise the local class so-
lution, such audits may not give insight in its ability to detect non-
conformities for plans not belonging to the original class solution. Since
over time, treatment plans may deviate unnoticed from the intended
class solution it is important to determine whether local QA systems can
detect errors for plans not belonging to the class solution. To achieve
this aim we distributed a limited set of pre-defined treatment plans
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using the radiotherapy (RT) extension to the Digital Imaging and
Communications in Medicine (DICOM) standard among the partici-
pating institutes. Using the same set of treatment plans allows the
comparison between the local QA and the audit findings of different
centres.
2. Materials and methods
The audit was performed at all 21 Dutch radiotherapy centres ex-
tended with one satellite location. Due to the lack of plan import op-
tions in the treatment planning software, in 3 of 22 sites plans had to be
generated by the institute itself. The results of these measurements were
not included in the analysis.
2.1. Treatment plans
Treatment plans of different complexity were generated: simple
(cervix) and complex (head and neck) IMRT and VMAT, and a stereo-
tactic (brain) VMAT plan. The audit plans reflect typical clinical IMRT
and VMAT delivery, selectively chosen such that all delivery parameters
were valid for the various combinations of TPS and linac delivery
system used by the participating centres, provided that particular
treatment technique was used clinically. For comparative and logistical
reasons, the audit was performed for 6 MV beams only. Based on the
occurrence of linac and TPS (Table 1), two plan sets were created: one
for Elekta (Elekta Instrument AB, Stockholm, Sweden) linacs, devised in
Pinnacle (Philips Medical Systems International B.V., Best, the Neth-
erlands) and one for Varian linacs, devised in Eclipse (Varian Medical
Systems, Palo Alto, California). We strived to keep the planning para-
meters as similar as possible (Table 2). The IMRT plans designed for the
Elekta linac used a step-and-shoot technique, whereas all other plans
used a sliding-window technique.
To assess the complexity of the plans, the segment shape, leaf mo-
tion and dose distribution were evaluated visually. To ensure accurate
dose measurements in the audit phantom, the isocentre was located in a
homogeneous high dose region. The linacs were grouped into two
types:
• Standard: Elekta MLCi(2) or Varian Clinac
• Advanced: Elekta Agility or Varian TrueBeam
Whenever possible, the simple plans were delivered on a standard
linac, the complex and stereotactic plans on an advanced one. For the
Varian linacs, the same treatment plans could be delivered on both linac
types, whereas the standard and advanced Elekta linacs are not inter-
changeable due to differences in head design (e.g. multi-leaf collimator
(MLC) and block design). Besides the differences in head design, there
was also a variation in availability of linac options (i.e. not all institutes
purchased the VMAT license on Elekta MLCi(2) linacs).
2.2. Audit preparation
The treatment plans, audit phantom Computer Tomography (CT)
scan, structure data set and the audit preparation manual were
distributed to all institutes. The institutes calculated the dose on a
2×2×2mm3 grid, using for the phantom a relative electron density
of 1.016 g/cm3 or mass density of 1.04 g/cm3 [16]. All other calculation
settings, such as dose algorithm, correction for treatment table were
according to the clinical protocol of the institute.
The institutes performed their own QA measurements in advance
using their local equipment (Table 3) and analysed the measurements
according to the audit criteria (Section 2.3).
2.2.1. Measurement equipment
All measurements and irradiation of calibration films for the audit
were performed using the OCTAVIUS® II (PTW Freiburg GmbH,
Freiburg, Germany) phantom and its associated inserts for the three
different dosimeters: ionisation chamber for an absolute dose mea-
surement, ionisation chamber array for a 2D measurement with high
reproducibility [11,17], and radiochromic film for a 2D measurement
with high resolution. The ionisation chamber was calibrated by the
Dutch Metrology laboratory, VSL; the 2D array was calibrated by its
manufacturer (PTW Freiburg GmbH, Freiburg, Germany) and checked
for constancy at the Netherlands Cancer Institute – Antoni van Leeu-
wenhoek.
2.2.1.1. Audit ionisation chamber. The point dose was measured using a
0.016 cm3 PinPoint ionisation chamber (TN31016 PTW Freiburg
GmbH, Freiburg, Germany) in combination with an electrometer
(UnidosWebline, PTW Freiburg GmbH, Freiburg, Germany). The
readings were converted to absolute dose according to the kQ
formalism [18].
2.2.1.2. Audit array. The OCTAVIUS® II with 729 plane-parallel
ionisation chambers was used for the array measurements and the
readings were recorded by the VeriSoft software (VeriSoft®, version 6.1,
PTW Freiburg GmbH, Freiburg, Germany [19]). To compensate for
daily output variations, the dose measured for a 10 × 10 cm2 field by
the central ionisation chamber of the array was used for normalisation.
2.2.1.3. Audit film. Film measurements were performed using
radiochromic films (Gafchromic EBT3, Ashland Specialty Group,
Wayne USA) from a single batch. For absolute dose calibration using
three colour channels [20], quarters of a film were irradiated in the
audit array with 0, 200, 400 and 600 MU (∼0–3.8 Gy) with a 10 × 10
cm2 field. The films were converted to dose according to the well-
established local protocol of the VU University Medical Centre
(Amsterdam, the Netherlands) [21,22].
2.3. Analysis
2.3.1. Ionisation chamber
The relative difference between the dose as calculated by the local
TPS and the audit measurement corrected for daily accelerator output
variation was defined as ΔN. ΔN was calculated by multiplying for each
plan the relative difference between the local TPS calculated dose and
the audit measurement, with the ratio of the local TPS calculated dose
and the audit measured dose for the 10 × 10 cm2 field in the
Table 1
Available linac vendor and TPS combinations in the Netherlands at the time of the audit measurements (October 2014 - August 2015).
Linac vendor TPS system Number of institutes RTP import
Elekta Monaco (Elekta Instrument AB, Stockholm, Sweden) 2 Not possible*
Elekta Oncentra (Elekta Instrument AB, Stockholm, Sweden) 2 DICOM
Elekta Pinnacle (Philips Medical Systems International B.V., Best, the Netherlands) 10 Pinnacle file format
Elekta Raystation (RaySearch, Stockholm, Sweden) 1 DICOM
Varian Eclipse (Varian Medical Systems, Palo Alto, California) 5 DICOM
Varian iPlan (BrainLab AB, Munich, Germany) 1 Not possible
* Limited DICOM import is possible from version 5.1 but not for externally generated phantom plans.
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OCTAVIUS® II phantom. ΔN was reported with a pass tolerance level
of ± 3%.
2.3.2. Array and film
The comparison between measured and computed dose distribu-
tions was performed in VeriSoft. The 2D measurements from the array
and film were compared with the 3D dose distribution from the TPS
using a 3D global gamma analysis [23], normalised to the maximum
computed dose in the phantom. For the simple and complex IMRT and
VMAT plans, the gamma pass rates were calculated using gamma
parameters 3mm and 3% [2,3,23], while for the stereotactic plan these
settings were 1mm and 5% [24]. A dose threshold of 10% of the
measured maximum dose and a pass criterion of 95% or higher was
used.
2.3.3. Evaluations
The agreement/disagreement between audit and the institute QA
results was evaluated per dosimeter, per treatment plan and per linac
type. For the latter, we combined the results of the Varian Clinac and
TrueBeam linacs since these could deliver the same plans and were
considered interchangeable, in contrast to the standard and advanced
Elekta linacs. The median, interquartile range and full range (min/max)
of the results for the three audit dosimeters and for institute QA results
were calculated per plan type.
3. Results
In total 82 plans were measured with each audit dosimeter: 18
simple IMRT; 14 simple VMAT; 18 complex IMRT; 16 complex VMAT
and 16 stereotactic VMAT. The plans measured on Elekta linacs were
52: 23 for the standard and 29 for the advanced type; on the Varian
linacs 28 plans were measured.
Most of the audit results agreed with the institute QA results (io-
nisation chamber: 74/82; array: 69/82; film: 62/82, see Fig. 1). When
considering only the plans measured on Elekta linacs, most ionisation
chamber (48) and array (44) audit measurements concurred with the
institute QA. Similar results were found for Varian linacs: 24 ionisation
chamber and 23 array measurements coincided with the institute QA.
For both ionisation chamber and array measurements, the agree-
ment/disagreement rates were not affected by plan complexity (Fig. 2),
whereas for film the disagreement rate seems to be slightly higher.
Moreover, the film results showed a greater number of fails and fewer
passes for increasing plan complexity.
The average of the ratio between calculated and measured dose for
the 10 × 10 cm2 reference field used in the calculation of ΔN was
0.7%±1.4% (1 SD). These values were largely influenced by the larger
spread in this ratio from the institutes using a dose-to-medium, Dm,
based TPS for which the ratio was 1.1%±1.5% (1 SD) compared to
0.2%±1.2% (1 SD) for institutes with a dose-to-water, Dw, based TPS.
For the array measurements, the range of the pass rates observed for
the simple (75.8%–100%) and complex VMAT plans (83.3%–100%)
was larger than the institute QA result range (80.3% –100% vs
93.2%–100%, respectively). For the film measurements, an unexpected
high number of outliers with extremely low (< 50%) pass rate was
found. Since this was primarily seen for one linac type, the film results
were excluded in the analysis per linac type.
The distribution of the measurements performed per linac type and
per plan type are summarized in Table 4. The average median ΔN value
per linac type for all plan types was −1.2% (standard Elekta), −2.2%
(advanced Elekta) and 0.8% (both Varian types). For the Elekta linacs,
the median pass rates per plan type were above 95% for the array
measurement except for the simple VMAT plan. The larger range for
this plan was not observed in the institute QA results, except for one
outlier (second to lowest was 92.1%). For the advanced Elekta linacs, a
larger range in pass rates was observed for the complex plans, which
Table 2
Audit treatment plan characteristics.











Preferable linac Standard Standard Advanced Advanced Advanced
Elekta MLCi(2) MLCi(2) Agility Agility Agility
Varian Clinac Clinac TrueBeam TrueBeam TrueBeam
Energy (MV) 6 6 6 6 6
Gantry angles (o) −144, −72, 0, 72, 144 178–182 −150, −110, −50, 0, 50, 110, 150 178–182,
182–178
178–182
Collimator angle (o) 20 20 20 20 20
Dose (cGy) at isoc
Plans for Elekta linac 184.5 193.2 144.8 146.3 353.8
Plans for Varian linac 188.5 181.5 146.5 143.6 357.5
Total # MU*
Plans for Elekta linac 418.6 391.4 511.7 388.8 675.0
Plans for Varian linac 878.3 565.0 1313.1 461.8 710.5
CPs/segments**
Plans for Elekta linac 35 90 60 180 90
Plans for Varian linac 643 178 1632 356 178
* 1 MU (Monitor Unit)= 1 cGy @ SSD=100 cm @ dmax.
** Number of segments for Step-and-Shoot (Elekta) IMRT, number of control points for dynamic delivery (Varian) IMRT and VMAT (Elekta, Varian).
*** Delivery technique: step-and-shoot for Elekta linacs and sliding-window for Varian linacs.
Table 3
QA equipment used by the institutes to measure the audit treatment plans.
ArcCHECK Sun Nuclear Corporation, Melbourne,
USA
2
Delta4 Scandidos AB, Uppsala, Sweden 5
EPIDdosimetry Elekta 1
EPIDdosimetry Varian 1
Film (EBT3) and point
dosimetry
Gafchromic EBT3, Ashland Specialty
Group, Wayne USA
2*
MatriXX IBA, Louvain-La-Neuve, Belgium 5
Octavius® II PTW, Freiburg, Germany 4**
Octavius® 4D PTW, Freiburg, Germany 2
* Film and ionisation chamber are used in combination with a slab phantom or the
OCTAVIUS® II phantom.
** In one institute, the PTW 729 array is used in combination with a slab phantom.
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was also observed in the institute QA. For the Varian linacs, a wider
range was observed for both the IMRT plans. However, this range was
in agreement with the institute QA results.
4. Discussion
A national audit on local methods for treatment plan verification
using one set of pre-defined plans has proven to be feasible. Overall, the
audit revealed a good agreement between calculated and measured
dose. The results of the audit were in line with other multi-institution
audits [5,7,8,13].
Overall, the local QA findings were in agreement with those of the
audit, possibly due to the observed high pass rate. The observed amount
of agreement between local QA and audit depends on the character-
istics of both audit and local QA equipment, plan complexity and the
evaluation parameters.
Kry et al. [25] found that local QA did not predict their audit results.
In our work, the QA methods, treatment plans and evaluation criteria
were more homogeneous, partly explaining this difference. In addition,
the audit was set-up prospectively and performed by the audit team,
thereby reducing the chance of handling errors. The measurements
failing both audit and institute QA were mostly related to the complex
plan types as presented by Lafond et al. showing lower gamma pass
rates for head and neck plans compared to prostate [26]. One institute
with a low pass rate for both audit array measurements and local QA
did not use the technique clinically since it was still developing the
corresponding class solution. For the others, the audit QA was poor due
to directional dependence of the audit phantom (see below). Un-
fortunately, not for all low pass rates a satisfactory explanation could be
found. All institutes have been informed of their own results with re-
spect to the average ones.
The level of agreement/disagreement between the audit and in-
stitute QA results was found to be dependent on the employed mea-
surement method. This variation is caused by the characteristics and
limitations of the employed device, in combination with characteristics
of the treatment plan.
In addition, the results are highly sensitive to the chosen pass/fail
limit and acceptance gamma criterion. Evaluating the array results with
a limit of 90% would increase the level of agreement (both pass) to
91%, the level of agreement (both fail) to 1% and reduce the level of
disagreement to 8%. The degree of agreement/disagreement between
the audit results and the institute QA is comparable for both Elekta and
Varian machines, despite the different set of plans used. Analysing our
array results shows an average pass rate of 97.9% (3%/3mm) and
96.2% (3%/2mm) for all Varian plans and an average pass rate of
96.6% (3%/3mm) and 93.4% (3%/2mm) for all Elekta plans. This
larger variation for the Elekta plans, with more variation in the com-
bination of linac/TPS vendor, is in accordance with the findings of
Clark et al. [11], although they found a bigger difference.
For the audit array, a relatively large number of measurements
disagreed for the simple and complex VMAT plans (audit failed, in-
stitute QA passed), which was most likely due to the measurement
Fig. 1. Pie-charts showing the agreement between results of the audit and the institute QA for all plans (upper panel), plans measured on Elekta linacs (lower left) and plans measured on
Varian linacs (lower right). Due to the large number of outliers, with extremely low pass rate, found for the film measurements, the film results were not taken into account in the analysis
per linac type. The four categories are: Agreement (pass), indicating that the plan passed both audit and institute QA; Agreement (fail), indicating that the plan failed both audit and
institute QA; Disagreement (audit pass/institute QA fail), indicating that the plan passed the audit but failed the institute QA; Disagreement (audit fail/institute QA pass), indicating that
the plan failed the audit but passed the institute QA. The acceptance criteria were: a gamma pass rate≥ 95% (5%/1mm for the stereotactic plan and 3%/3mm for the other plans) for the
2D measurements (array and film); a relative difference within ± 3% for the point measurements (ionisation chamber).
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device itself. The response of the audit array has a directional depen-
dence influencing the outcome of the measurements on Elekta linacs
[27–29], in particular because the phantom was defined as homo-
geneous in the TPS [29] and a substantial number of MU’s was deliv-
ered at the affected angles (90 and 270°). For the plans for Varian li-
nacs, the MU’s were more evenly distributed over all angles. The use of
for example the OCTAVIUS® 4D array could have mitigated this [16].
A wider range in results was observed for both simple and complex
IMRT plans on Varian machines than for Elekta linacs, which was in
agreement with the institute QA results. This could be explained by the
more complex sliding-window delivery technique used by Varian linacs
compared to the step-and-shoot delivery of Elekta machines [30,31].
For the Varian linac we observed a higher disagreement rate (audit
pass, institute failed), which could be explained by the higher spatial
Array                                                                            Film Fig. 2. Pass rate for the audit results (array: left column and
film: right column) as a function of the institute QA for all
measurements subdivided according to the plans. The pass
rates were calculated using gamma parameters 5%/1mm
for the stereotactic plan and 3%/3mm for the other plans.
Please note the difference in scale for the y-axis between the
Array and Film results.
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resolution of the local QA equipment used by these institutes.
A larger number of outliers with a very low gamma pass rate was
observed for the film results compared to the other measurements
methods. In these measurements, on average 10 cGy (i.e. 5% on
200 cGy) less was recorded than expected, corresponding to a pass rate
below 80% using 3% and 3mm. This is explained by the 5% variation in
the local audit film calibration curves, being much larger than
the∼1.5% variation expected from the standardised procedure for film
analysis [22,32–35]. Absolute film dosimetry is less accurate than re-
lative film dosimetry [34] but no clear reason was found for the dif-
ferences in the local calibration curves. Further investigations to clarify
this are on-going, but beyond the scope of this work.
The QA methods used in this audit were designed to be insensitive
to differences in dose calculation properties, for example type and
version of TPS, dose algorithm (Dw based or Dm based), Hounsfield Unit
to electron density conversion and inclusion of the treatment couch.
This is confirmed by the small variation in ΔN over all the institutes for
the different plan types, and by the differences between Dm and Dw
based TPS for the ratio between calculated and measured 10 × 10 cm2
field dose. Other tests should elucidate such aspects.
The main challenges in the audit were the workload and cir-
cumventing RT-Plans DICOM import problems. Separate plans for the
different linac types had to be created causing unavoidable differences
among these plans. For Elekta linacs, certain machine settings and
limits can be chosen by the user, regardless of the TPS being used. To
ensure that the audit treatment plans could be delivered and the dose
could be calculated by each institute, the most conservative settings
(e.g. maximum leaf speed, minimum and maximum dose rate) were
chosen. For Varian users, such freedom in machine settings and limits is
not available.
Another limitation is that, for comparison purposes, the audit team
defined the evaluation criteria according to national guidelines which
may not be exactly the same as the ones used locally. Despite national
guidelines [2,3], the evaluation criteria varied slightly among institutes
but the impact on the results of this work is negligible. Finally, small
differences exist in the implementation of the gamma analysis between
QA vendors.
Since the performance of the local QA devices is to a large extent
energy independent, we believe that this evaluation of local QA
methods can be translated to other energies as well.
Concluding, this work described the implementation and results of a
national audit on validation of clinically used QA methods for plan-
specific verification. For this, the same set of treatment plans was used
for all institutes enabling a multi-centre comparison of the local QA
results not influenced by other steps of the treatment chain such as
planning protocol and optimization algorithms. The results showed that
overall local QA of IMRT and VMAT plans in the Netherlands gave si-
milar results as those of an external audit. However, the disagreement
rates between local and audit QA results indicate that independent
audits of QA systems, combined with other types of dosimetry audits,
Table 4
Median values, range (min/max) and interquartile range (IQR) of the audit and institute QA results among all measurements for the Elekta linacs (MLCi(2) or Agility) and the Varian
linacs (Clinac and TrueBeam).
Plan type Linac type Number of measure-ments Ionisation chamber Array Institute QA













































































































For all plans combined, the average median ΔN was −1.3 ± 0.6% (1 standard deviation, SD); the average median gamma pass rate was close to 100%, for both the film (99.1%) and
array (99.7%) measurements as well as the institute QA result (99.7%).
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are indispensable tools in the continuous improvement of radiotherapy
as part of the treatment for patients with cancer.
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